| Literature DB >> 33198787 |
Ana Berbel Caban1, Theodore R Pak2, Ajay Obla2, Amy C Dupper1, Kieran I Chacko2, Lindsey Fox1, Alexandra Mills1, Brianne Ciferri2, Irina Oussenko2, Colleen Beckford2, Marilyn Chung2, Robert Sebra2,3,4,5, Melissa Smith2,3, Sarah Conolly6, Gopi Patel1,6, Andrew Kasarskis2,3,7, Mitchell J Sullivan2, Deena R Altman1,2, Harm van Bakel8,9.
Abstract
BACKGROUND: Whole-genome sequencing (WGS) is increasingly used to map the spread of bacterial and viral pathogens in nosocomial settings. A limiting factor for more widespread adoption of WGS for hospital infection prevention practices is the availability of standardized tools for genomic epidemiology.Entities:
Keywords: MRSA bacteremia; Nosocomial outbreaks; PathoSPOT; Visualization toolkits; Whole-genome sequencing
Year: 2020 PMID: 33198787 PMCID: PMC7670629 DOI: 10.1186/s13073-020-00798-3
Source DB: PubMed Journal: Genome Med ISSN: 1756-994X Impact factor: 11.117
Fig. 1PathoSPOT comparative genome analysis of 221 MRSA isolates. a Overview of the PathoSPOT whole-genome comparison framework. b Maximum-likelihood phylogenetic trees produced from core-genome SNVs identified from Parsnp whole-genome alignments of 4 clusters identified at a Mash score threshold of 0.02. Trees are annotated with MLST and SCCmec information (key is shown on the right) and clonal complexes (bottom). Scale bars indicating the number of substitutions per site in the phylogeny and the percentage of core-genome coverage among all sequences are shown at the center of each tree
Fig. 2Identification of clonal clusters among 197 MRSA bacteremia cases. a Beeswarm plot of MRSA cases with sequenced isolate genomes during the surveillance period. Cases with isolates separated by ≤ 15 core-genome SNVs are grouped in clonal clusters, each highlighted with a distinct color. The number of isolates in each cluster is indicated in the color key. b Histogram of pairwise core-genome SNV distances for isolates obtained from the same patient (black bars) and isolates obtained from different patients (gray bars). The vertical red line indicates the 15-SNV threshold for clonality. c Heatmap of pairwise core-genome SNV distances between clustered isolates. Clusters are grouped along the diagonal and colored as in a, with decreasing shading reflecting an increased pairwise SNV distance. Closed squares and open squares are used for isolates from different patients or the same patient, respectively. All date information in this figure was recoded to protect health information. An interactive version of this figure is available at https://pathospot.org/?fig=2
Fig. 3Epidemiological timeline of the long-term outbreak. a Phylogenetic tree of core-genome SNV differences (left) with corresponding locations of each variant relative to the first outbreak isolate that was obtained from p40 (right). Non-synonymous and synonymous variants are highlighted in black and gray, respectively. Isolates in subclades sharing three or more variants (shaded areas) are identified by distinct tip symbols at each branch. b PathoSPOT timeline integrating genomic and epidemiological data. Rows correspond to patients, with admission periods in hospital wards shown as horizontal bars, colored as in a. Sequenced isolates are shown as different symbols matching those used in the phylogenetic tree in a. Shaded arcs signify ward-level patient overlap within 24 h. Other positive or negative clinical test results are indicated by gray symbols, with a key shown below. The scale is shown at the top. c Summary of key outbreak events in wards, derived from the epidemiological timeline. See the main text for details. All date information in this figure was recoded to protect health information. An interactive version of this figure is available at https://pathospot.org/?fig=3
Outbreak patients vs. non-outbreak patients with MLST 105 isolates
| Factor | Outbreak patients | Non-outbreak patients | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | OR (95% CI) | |||||
| Male | 11 (69) | 21 (62) | 1.36 (0.39–4.82) | 0.63 | ||
| Non-Hispanic White | 5 (31) | 14 (41) | Reference | |||
| Non-Hispanic Black | 3 (19) | 9 (26) | 0.93 (0.18–4.90) | 0.94 | ||
| Hispanic/Latino/Asian | 5 (31) | 6 (18) | 2.33 (0.49–11.17) | 0.29 | ||
| Unknown | 3 (19) | 5 (15) | 1.68 (0.29–9.75) | 0.56 | ||
| 18–54 years | 6 (38) | 7 (21) | Reference | |||
| 55–69 years | 5 (31) | 9 (26) | 0.65 (0.14–3.04) | 0.58 | ||
| ≥ 70 years | 5 (31) | 18 (53) | 0.32 (0.07–1.41) | 0.13 | ||
| History of IV drug use | 2 (13) | 2 (6) | 2.29 (0.29–17.90) | 0.43 | ||
| HIV | 1 (6) | 3 (9) | 0.69 (0.07–7.19) | 0.76 | ||
| Home | 12 (75) | 17 (50) | Reference | |||
| NH/Rehab/LTACH | 2 (13) | 11 (32) | 0.26 (0.05–1.38) | 0.11 | ||
| Other hospitals | 2 (13) | 6 (18) | 0.47 (0.08–2.75) | 0.40 | ||
| Prior hospital admission (90 days) | 10 (63) | 23 (68) | 0.80 (0.23–2.76) | 0.72 | ||
| CO-MRSA | 4 (25) | 24 (71) | Reference | Reference | ||
| HO-MRSA | 12 (75) | 10 (29) | ||||
| Presence of invasive deviceA | 14 (88) | 27 (90) | 0.78 (0.12–5.21) | 0.80 | ||
| Receiving cancer treatmentB | 7 (44) | 2 (6) | ||||
| 0–3 | 4 (25) | 9 (26) | Reference | |||
| ≥ 4 | 12 (75) | 25 (74) | 1.08 (0.28–4.23) | 0.91 | ||
| History of MRSA colonization | 6 (38) | 16 (47) | 0.68 (0.20–2.28) | 0.53 | ||
| Skin sourceC | 4 (25) | 7 (21) | 1.29 (0.32–5.24) | 0.73 | ||
| Pneumonia | 1 (6) | 6 (18) | 0.31 (0.03–2.83) | 0.30 | ||
| Vascular access*,† | 9 (56) | 9 (26) | ||||
| Others/undetermined | 2 (13) | 12 (35) | 0.26 (0.05–1.35) | 0.11 | ||
| Persistent bacteremia (≥ 5 days) | 2 (13) | 9 (26) | 0.40 (0.08–2.10) | 0.28 | ||
| ICU admission prior to BSI | 4 (25) | 3 (9) | 3.44 (0.67–17.73) | 0.14 | ||
| Intubated prior to MRSA BSI | 4 (25) | 2 (6) | 5.33 (0.86–33.00) | 0.07 | ||
Bold indicates significance at ≤ 0.05
Abbreviations: BSI bloodstream infection, HIV human immunodeficiency virus, ICU intensive care unit, IV intravenous, NHSN National Healthcare Safety Network
AIncludes devices such as a pacemaker, any vascular access, orthopedic hardware, foley catheter, arteriovenous graft placement, percutaneous endoscopic gastronomy (PEG), ostomy, or any type of urinary collection at the time of first positive bloodstream infection
BIncludes patients actively receiving cancer treatment through a central venous catheter prior to bacteremia in the outpatient or inpatient setting
CSkin source includes skin and soft tissue infections, thrombophlebitis due to peripheral IV catheters
*Variable not included in the multivariate analysis in order to prevent collinearity between receiving cancer treatment and vascular access
†Vascular access devices include a non-tunneled central venous catheter, tunneled catheter (hickman or permacath), implanted port, peripherally inserted central catheter (PICC line), and arteriovenous graft (AVG) and fistula (AVF)